Hydroxy derivatives of tamoxifen

Area of Science:

• Medicinal Chemistry
• Endocrinology
• Pharmacology

Background:

• Tamoxifen is a selective estrogen receptor modulator used in breast cancer treatment.
• Understanding structure-activity relationships is crucial for developing more effective therapies.
• Estrogen receptor binding affinity (RBA) is a key determinant of tamoxifen's efficacy.

Purpose of the Study:

• To synthesize and evaluate novel tamoxifen derivatives with substitutions on the phenyl group.
• To investigate how structural modifications impact estrogen receptor binding affinity (RBA).
• To assess the anti-cancer activity of promising derivatives against MCF-7 cells.

Main Methods:

• Synthesis of various tamoxifen derivatives, including hydroxylated and methylated compounds.
• Acid-catalyzed dehydration of tertiary alcohols as a key synthetic step.
• Measurement of RBA using the estrogen receptor of rat uterus relative to estradiol (E2).
• In vitro growth inhibition assays against MCF-7 mammary tumor cell line.

Main Results:

• Trans isomers of 2-hydroxy, 2-methyl, 2,4-dihydroxy, and 4-hydroxy-2-methyl derivatives were selectively obtained.
• 2-Hydroxytamoxifen exhibited significantly lower RBA (0.1%) compared to tamoxifen and 2-methyltamoxifen (~1%).
• The 4-hydroxy-2-methyl derivative demonstrated high RBA and potent growth inhibitory activity against MCF-7 cells, similar to 4-hydroxytamoxifen.
• Derivatives hydroxylated at positions 3 or 4, and a 5-hydroxy-1-pentene analogue, showed very low RBA.

Conclusions:

• Structural modifications, particularly hydroxylation and methylation at specific positions, significantly influence tamoxifen's RBA and anti-cancer activity.
• The 4-hydroxy-2-methyl tamoxifen derivative is a promising candidate for further investigation due to its high efficacy.
• This study provides valuable insights into the structure-activity relationships of tamoxifen, aiding in the design of next-generation SERMs.